Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05549661 · ClinicalTrials.gov registry record · Phase 1
Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms
A Phase 1 study of Recurrent Chronic Myelomonocytic Leukemia and Refractory Chronic Myelomonocytic Leukemia, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
- 1
- Study location
NCT05549661 is a Phase 1 study of Recurrent Chronic Myelomonocytic Leukemia and Refractory Chronic Myelomonocytic Leukemia that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 25 participants, below the 62-participant average among 10 other Recurrent Chronic Myelomonocytic Leukemia trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state.
The verdict
NCT05549661, a Phase 1 study of Recurrent Chronic Myelomonocytic Leukemia and Refractory Chronic Myelomonocytic Leukemia, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I trial evaluates the safety, effectiveness, and best dose of onvansertib for the treatment of patients with chronic myelomonocytic leukemia and Myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap neoplasms that has come back (recurrent) or that does not respond to treatment (refractory). Onvansertib is a drug that binds to and inhibits an enzyme called PLK1, preventing cancer cell proliferation and causing cell death.
Conditions Studied
Interventions
- PROCEDURE Biospecimen Collection
- PROCEDURE Ultrasound Imaging
- PROCEDURE Bone Marrow Aspiration and Biopsy
- DRUG Onvansertib
Study Locations (1)
Minnesota
- Mayo Clinic in Rochester - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2023-04-04 |
| Est. Completion | 2027-12-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05549661
The ClinicalTrials.gov registry entry for NCT05549661 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 62-participant average among 10 other Recurrent Chronic Myelomonocytic Leukemia trials with a reported enrollment target (60% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 6 conditions, with Recurrent Chronic Myelomonocytic Leukemia appearing as the primary indexed condition, and to 4 interventions - of which Biospecimen Collection is the first listed.
NCT05549661 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT05549661 about?
NCT05549661 is a clinical study titled "Onvansertib for the Treatment of Recurrent or Refractory Chronic Myelomonocytic Leukemia and Myelodysplastic Syndrome/MPN Overlap Neoplasms". This phase I trial evaluates the safety, effectiveness, and best dose of onvansertib for the treatment of patients with chronic myelomonocytic leukemia and Myelodysplastic syndrome/myeloproliferative neoplasm (MDS/MPN) overlap neoplasms that has come back (recurrent) or that does not respond to trea...
What is the current status of trial NCT05549661?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2023-04-04. Estimated completion is 2027-12-01.
What conditions does trial NCT05549661 study?
This clinical trial studies the following conditions: Recurrent Chronic Myelomonocytic Leukemia, Refractory Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Myelodysplastic/Myeloproliferative Neoplasm, Not Otherwise Specified.
What interventions are being tested in trial NCT05549661?
The interventions under investigation include: Biospecimen Collection (PROCEDURE), Ultrasound Imaging (PROCEDURE), Bone Marrow Aspiration and Biopsy (PROCEDURE), Onvansertib (DRUG).
Who is sponsoring clinical trial NCT05549661?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05549661 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Chronic Myelomonocytic Leukemia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Seclidemstat and Azacitidine for the Treatment of Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia
RECRUITING · Phase 1
-
Azacitidine and Quizartinib for the Treatment of Myelodysplastic Syndrome or Myelodysplastic/Myeloproliferative Neoplasm With FLT3 or CBL Mutations
RECRUITING · Phase 1
-
CLAG-M or FLAG-Ida Chemotherapy and Reduced-Intensity Conditioning Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia, Myelodysplastic Syndrome, or Chronic Myelomonocytic Leukemia
RECRUITING · Phase 1
-
Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse
RECRUITING · Phase 1
-
Azacitidine, Venetoclax, and Gilteritinib in Treating Patients With Recurrent/Refractory FLT3-Mutated Acute Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or High-Risk Myelodysplastic Syndrome/Myeloproliferative Neoplasm
RECRUITING · Phase 1
-
Q702 for the Treatment of Patients With Hematologic Malignancies
RECRUITING · Phase 1
Explore more on PlainTrial
Recurrent Chronic Myelomonocytic Leukemia
All registered trials for this condition
Refractory Chronic Myelomonocytic Leukemia
All registered trials for this condition
Minnesota
All trials with a study site in Minnesota
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.